Skip to main content
. 2020 Jan 7;15(1):e0226844. doi: 10.1371/journal.pone.0226844

Fig 2. Percentage (95% CI) of patients continuing RAASi* therapy: By treatment group and exposure classification (CE, ITT).

Fig 2

*RAASi included: ACE inhibitors, ARBs, MRAs, and DRIs. CE, continuous exposure; CI, confidence interval; ITT, intention-to-treat; NoKb, no potassium binder; RAASi, renin-angiotensin-aldosterone system inhibitor; SPS, sodium polystyrene sulfonate.